Peptide questions · SS-31
SS-31 side effects: what studies and users report
Reviewed Evidence: EmergingPublished by PepVault
The side effects most commonly reported for SS-31 are injection site reaction, nausea and mild headache; the library’s evidence on it includes controlled trials in people.
The library holds no separate safety note for SS-31.
What is commonly reported with SS-31
- Injection site reaction
- Nausea
- Mild headache
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 18) |
|---|---|
| Injection site reaction | 4: MOTS-c, Epitalon, Pinealon, Klotho |
| Nausea | None: listed for SS-31 alone |
| Mild headache | 2: Epitalon, DSIP |

Which SS-31 side effects the longevity group shares
Across the 19 longevity compounds in the library, the effects listed most often are injection site reaction (5 of 19), injection-site discomfort (3 of 19), injection-site redness or itch (3 of 19) and mild headache (3 of 19). SS-31 shares 2 of its 3 listed effects with at least one other longevity compound; nausea is listed for SS-31 alone.
Where the SS-31 reports come from
The library rates the evidence on SS-31 as emerging: mostly preclinical, with limited human data.
Of the library’s 5 research notes on SS-31, 2 rest on clinical data and 3 on community reports.
Our 14 study pages on SS-31: 8 randomized trials, 2 clinical trials, 3 animal studies (mice) and 1 observational study.
So SS-31 has controlled trials in people to set its listed effects against.
What our SS-31 study pages report on safety
SS-31 (elamipretide) eye drops missed main vision goal in LHON trial
Randomized trial, human, 2024: Elamipretide was well tolerated, most side effects were mild to moderate and went away on their own, and there were no serious side effects.
SS-31: 96.1 m longer 6-minute walk at 168 weeks in TAZPOWER
Clinical trial, human, 2024: Elamipretide was well tolerated, and reactions at the injection site were the most common side effect. For Barth syndrome, this small extension suggests elamipretide's gains in walking distance and fatigue held up through 168 weeks, with injection-site reactions as the most common side effect.
SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial
Randomized trial, human, 2023: The drug was tolerated well, and most side effects were mild or moderate. In a large placebo-controlled trial, elamipretide was tolerated well but did not improve walking distance or fatigue over 24 weeks in primary mitochondrial myopathy.
SS-31: walk distance rose with dose in 5-day MMPOWER trial
Randomized trial, human, 2018: No significant differences showed up in the other efficacy measures or in safety. This was a small trial with only 5 days of treatment, so it can't show longer-term benefit or safety.
SS-31 did not significantly cut infarct size in EMBRACE STEMI
Randomized trial, human, 2016: SS-31 also did not improve the pre-planned MRI, angiography, ECG or clinical outcomes, and it was safe and well tolerated. In a randomized human trial in heart attack patients having PCI, SS-31 was well tolerated but did not significantly reduce heart muscle damage compared with placebo.
Questions people ask
What are the side effects of SS-31?
The side effects most commonly reported for SS-31 are injection site reaction, nausea and mild headache; the library’s evidence on it includes controlled trials in people.
Do SS-31’s side effects come from human studies?
The library rates the evidence on SS-31 as emerging, and the library’s evidence on it includes controlled trials in people.
Which SS-31 side effects are its own?
Among the longevity compounds, the library lists nausea for SS-31 alone.